The U.S. Food and Drug Administration has declined to approve Ultragenyx Pharmaceutical's experimental gene therapy to treat ...

Sarepta Therapeutics said on Wednesday it would lay off 36% of its workforce, or about 500 employees, after the recent deaths of two patients who had received its gene therapy Elevidys.

The gene-therapy company is restructuring, laying off 36% of its workforce and making changes to its executive team.

CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

The company is also pausing research for several treatments it has been developing for another form of muscular dystrophy.

This is a developing story and will be updated as more information becomes available. | Sarepta Therapeutics has laid off 500 staffers, or 36% of its workforce, as part of a strategic restructuring ...

The drastic cost-cutting move followa the deaths of two teenagers that forced the company to restrict usage of its gene ...

Sarepta Therapeutics faces a challenging period as it navigates recent setbacks with its groundbreaking gene therapy, leading ...

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

The manufacturing-related rejection for UX111 is more than a setback for Ultragenyx, as it also delays a key test of the new ...

Boyang Wang on Targeting Underfunded Longevity Projects SINGAPORE, SG / ACCESS Newswire / July 16, 2025 / Immortal Dragons, a ...

While the CRL derails a near-term clearance, one analyst described the rejection as more of “a speed bump to approval, rather ...